PPARG and cancer: Because PPARγ is expressedby many malignant tumors, activation of PPARγ by 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), the most potent endogenous ligand for PPARγ [7], and the synthetic PPARγ ligands (e.g., rosiglitazone, pioglitazone, troglitazone, and indomethacin)have been regarded as a novel therapeutic approach for certain humanmalignancies through growth inhibition, induction of apoptosis and terminaldifferentiation, and inhibition of angiogenesis [8].